**FOI Ref: 6599**

**Category(ies): Clinical - Drugs**

**Subject: The usage of Biologic and Biosimilar Products within Rheumatology**

**Date Received: 07/09/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
* Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Baricitinib [Olumiant]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Filgotinib [Jyseleca]
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
* Rituximab [MabThera]
* Rituximab Biosimilars
* Sarilumab [Kevzara]
* Secukinumab [Cosentyx]
* Tocilizumab [Ro Actemra]
* Tofacitinib [Xeljanz]
* Upadacitinib [Rinvoq]
* Ustekinumab [Stelara]

  | * Abatacept [Orencia] – 12
* Adalimumab [Humira] – 0
* Adalimumab Biosimilars – 65
* Apremilast [Otezla] – 0
* Baricitinib [Olumiant] - 38
* Certolizumab [Cimzia] – 4
* Etanercept [Enbrel] – 1
* Etanercept Biosimilars – 101
* Filgotinib [Jyseleca] – 0
* Golimumab [Simponi] – 4
* Guselkumab [Tremfya] – 0
* Infliximab [Remicade] – 0
* Infliximab Biosimilars – 0
* Ixekizumab [Taltz] – 2
* Risankizumab [Skyrizi] – 0
* Rituximab [MabThera] – 0
* Rituximab Biosimilars – 0
* Sarilumab [Kevzara] – 0
* Secukinumab [Cosentyx] – 6
* Tocilizumab [Ro Actemra] – 7
* Tofacitinib [Xeljanz] – 0
* Upadacitinib [Rinvoq] – 2
* Ustekinumab [Stelara] – 1
 |
| 1. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.
* Abatacept [Orencia]
* Adalimumab [Humira]
* Adalimumab Biosimilars
* Apremilast [Otezla]
* Certolizumab [Cimzia]
* Etanercept [Enbrel]
* Etanercept Biosimilars
* Golimumab [Simponi]
* Guselkumab [Tremfya]
* Infliximab [Remicade]
* Infliximab Biosimilars
* Ixekizumab [Taltz]
* Risankizumab [Skyrizi]
 | We are unable to provide this level of detail as we do not have a clinical data base search function on the Trust EPR system, and it would *exceed the appropriate time/cost limit under Section 12(1) of the FOI Act* to manually search.*To process your request would exceed the appropriate time/cost limit under Section 12(1) of the FOI Act.**Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the ‘appropriate limit’, as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request by undertaking a manual review of all the documents would significantly exceed the above limit.* |